“gw-pharmaceuticals” Archives

in
Entry Author Date Location
With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug 09/30/20 New York
Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More 08/07/20 National
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More 04/10/20 National
For GW Pharma CEO Justin Gover, The CBD Trend Started 20 Years Ago 08/26/19 San Diego
Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D 06/18/19 Boston
Stoke Therapeutics Preps IPO to Bring Dravet Syndrome Drug to Clinic 05/24/19 Boston
Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More 05/10/19 National
FDA Refuses to Review Zogenix Seizure Drug, Says File Not Complete 04/08/19 San Francisco
With $90M Round, Stoke Eyes a “Spinraza For Epilepsy” And a 2019 IPO 10/23/18 Boston
Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More 07/13/18 National
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug 07/12/18 San Francisco
Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On 06/29/18 National
East Coast Bio Roundup: PCSK9 Battle, NYU Startups, Blueprint & More 03/17/16 Boston
Page 1 of 1